DBV Technologies reports Q1 net loss of $47.6M; cash of $229M into Q2 2027

DBV Technologies S.A.

2026-Q1 EPS reported -$0.11 revenue$900,000

Net loss of $47.6M ($0.11 per share) vs $27.1M ($0.26) in Q1 2025; loss per share improved due to equity base from PIPE.
Cash and cash equivalents $229M as of March 31, 2026, up from $194M at year-end 2025; funding into Q2 2027.
R&D expenses rose to $33.4M (from $21.5M) driven by COMFORT Toddlers study, BLA readiness, and pre-commercial inventory build.
SG&A expenses increased to $10.5M (from $5.6M) as company builds U.S. commercial infrastructure ahead of potential launch.
BLA submission for VIASKIN Peanut Patch (ages 4-7) planned H1 2026; toddler BLA H2 2026; Phase 2 THRIVE study in infants planned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

DBV Technologies S.A. reported the three months ended March 31, 2026 results: net income $47.6 million, EPS $(0.11).

Period: the three months ended March 31, 2026
Net income: $47.6 million
EPS: $(0.11)
Result: reported results

Exact text from the filing

Net loss was $47.6 million for the three months ended March 31, 2026

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

DBV Technologies S.A. filing history →

Source: SEC EDGAR

accession 0001193125-26-197921

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.